Ophthalmology in China

Previous Articles     Next Articles

Seventy-year progress in the pharmaceutical treatment of fundus diseases

ZHOU Nan, WEI Wen-bin   

  1. Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2019-09-08 Online:2019-09-25 Published:2019-09-24
  • Contact: WEI Wen-bin, Email: tr_weiwenbin@163.com

Abstract: Since the founding of New China 70 years ago, the level of diagnosis and treatment of fundus diseases in China has been rapidly improved. New treatment methods and new drugs have been introduced into China, such as Ranibizumab, Afibercept, dexamethasone sustained-release agents, etc., which has greatly promoted the development of treatment of fundus diseases in China. Especially the emergence of small molecule antibody drugs represented by anti-vascular endothelial growth factor (VEGF) drugs and the promotion of intravitreal injection are milestones in the field of fundus disease treatment, which has changed the previous treatment methods for fundus vascular diseases, reduced the amount of vitrectomy, greatly improved the prognosis of the disease. Homemade humanized recombinant fusion protein Conbercept enriches the spectrum of anti-VEGF drugs. With the development of medicine and diversification of treatment technology for fundus diseases, the treatment level of fundus diseases in China is further in line with the international standards. (Ophthalmol CHN, 2019, 28: 321-324)

Key words: fundus diseases, medical treatment